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LMP knockout miceWe have previously demonstrated that proteasome serves as a central regulator of inﬂammation and macro-
phage function. Until recently, proteasomes have generally been considered to play a relatively passive role in
the regulation of cellular activity, i.e., any ubiquitinated proteinwas considered to be in discriminatively targeted
for degradation by the proteasome.We have demonstrated, however, by using speciﬁc proteasome protease in-
hibitors and knockout mice lacking speciﬁc components of immunoproteasomes, that proteasomes (containing
X, Y, and Z protease subunits) and immunoproteasomes (containing LMP7, LMP2, and LMP10 protease subunits)
havewell-deﬁned functions in cytokine induction and inﬂammation based on their individual protease activities.
We have also shown that LPS-TLR mediated signaling in the murine RAW 264.7 macrophage cell line results in
the replacement of macrophage immunoproteasomal subunits. Such modiﬁcations serve as pivotal regulators
of LPS-induced inﬂammation. Our ﬁndings support the relatively novel concept that defects in structure/function
of proteasome protease subunits caused by genetic disorders, aging, diet, or drugs may well have the potential
to contribute to modulation of proteasome activity. Of particular relevance, we have identiﬁed quercetin and
resveratrol, signiﬁcant constituents present in berries and in red wine respectively, as two novel proteasome
inhibitors that have been previously implicated as disease-modifying natural products. We posit that natural
proteasome inhibitors/activators can potentially be used as therapeutic response modiﬁers to prevent/treat
diseases through pathways involving the ubiquitin–proteasome pathway (UP-pathway), which likely functions
as a master regulator involved in control of overall inﬂammatory responses. This article is part of a Special Issue
entitled: Ubiquitin Drug Discovery and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Lipopolysaccharides (LPS) serve as a prototype microbe-derived
activator ofmacrophages via TLR4-dependent signaling, leading to gen-
eration of multiple pro- and anti-inﬂammatory mediators through
either the MyD88-independent (TRIF/TRAM) or MyD88-dependent
pathway (Fig. 1). When produced in excess in response to LPS, these
proinﬂammatory mediators can promote the development of systemic
inﬂammation that can progress to a life-threatening condition termed
septic shock. Results fromour recently completed studies have revealed
that macrophage proteasomes play a pivotal role in the regulation of
LPS-induced signaling and regulation of gene expression and, via this
mechanism, are key regulators of macrophage-dependent inﬂammato-
ry responses [1–11]. The 26S proteasomes are multi-protein protease
complexeswhich serve a key function inmammalian cells by degrading
ubiquitinated proteins. ATP is required for this process. The 26Sbiquitin Drug Discovery and
l Sciences, 2411 Holmes Street,
O 64108, USA. Tel.: +1 816 235
444.
rights reserved.proteasome consists of a 19S regulatory complex and a 20S proteasome
complex, the latter of which has been established to contain six differ-
ent subunits (X, Y, Z, LMP2, LMP7, and LMP10), each of which possesses
a speciﬁc protease activity. Subunits X and LMP7 possess chymotrypsin-
like (CT) enzymatic activity that is responsible for protein sites after
tyrosine or phenylalanine residues, Y and LMP2 possess post-acidic
(PA) activity that is responsible for cleaving aspartic or glutamic acidic
residues, while Z and LMP10 possess trypsin-like (T) activity that
targets after arginine, lysine, or basic residues [12–14] as indicated in
Fig. 2A. One of the important contributions of proteasomes in host
defenses was originally recognized because of their role in antigen pre-
sentation, but proteasomes have now been shown to contribute to the
regulation of a number of additional cellular functions that are impor-
tant to innate cellular defenses [12–15].
We initially undertook studies designed to assess the contribution
of proteasomes to LPS-induced inﬂammatory responses in murine
macrophages, particularly from the perspective of their potential to
serve as therapeutic targets for the treatment of sepsis [6]. We have
vigorously pursued this goal over the past several years, and the re-
sults of extensive published studies by us, and others, have served
to highlight the role of the ubiquitin–proteasome (UP) pathway as a
pivotal regulator of LPS-induced inﬂammation and cytokine induc-





































Fig. 1. LPS-induced signaling pathways in macrophages. Pathways 1 and 3 utilize MyD88/MAL as the adaptor molecules, while Pathways 2a and 2b utilize the TRIF/TRAM adaptor
molecules.
2088 N. Qureshi et al. / Biochimica et Biophysica Acta 1823 (2012) 2087–2093research ﬁndings that describe the function of the proteasome
proteolytic subunits.2. Current paradigm of agonist-induced signaling in
murine macrophages
The current paradigm for TLR4 signaling (Fig. 1) has evolved con-
siderably since our initial work ﬁrst provided evidence that the UP-
pathway and, more speciﬁcally, chymotrypsin (CT)-like and trypsinFig. 2. A. The six proteases of the proteasome. Subunits X, LMP7 have the chymotrypsin‐
like activity, Y, LMP2 have the post-acidic and Z, LMP10 have the trypsin-like activity.
B. LPS treated RAW 264.7 cells manifest altered XYZ/LMP subunits and proteolytic activi-
ties of the proteasome. The ratio of chymotrypsin-like/post-acidic activity increases when
the proteasomes contain LMP subunits upon LPS treatment. After use, the subunits of the
proteasomes are ubiquitinated and degraded by the proteasome.(T)-like sites in the proteasome, were involved in LPS-induced signal-
ing in murine macrophages [2,3,6,7], as described later in Section 3.
LPS is known to interact with the TLR4/MD2 complex at the macro-
phage surface, leading to recruitment of two pairs of adapter proteins
(TIRAP (Mal)/MyD88 and TRAM/TRIF) to the TLR4 intracellular
“Toll-IL-1R resistance” (TIR) domain [16–18].MyD88 and TRIF facilitate
docking of downstream kinases and other proteins that trigger two
major signal transduction pathways termed the MyD88-dependent
(Pathway 1) and the TRIF-dependent (Pathways 2a and 2b). IRAK4 and
IRAK1 dock onto MyD88 and are activated through phosphorylation
[phosphate groups are shown in red circles in Fig. 1] [9]. These events
lead to ubiquitination of IRAK1 (ubiquitinated via K48- or K63-linked
ubiquitins [blue and green chains, respectively, in Fig. 1]), which results
in their dissociation from the TLR4 complex, and subsequent association
of IRAK1 with TRAF6 and associated molecules. TRAF6, an E3 ubiquitin
ligase, becomes auto-ubiquitinated with K63 chains, which do not signal
degradation by the proteasome. Ubiquitinated TRAF6 then ubiquitinates
IκB kinase (IKKγ) that, in turn, phosphorylates IκB, that is complexed to
NF-κB in the cytosol [19–24]. Once phosphorylated, the IκB component
of the IκB–NF-κB complex is ubiquitinated with K48 chains, leading to
its degradation by the proteasome. IκB serves as the primary inhibitory
component of the NF-κB complex, so its degradation leads to the activa-
tion of NF-κB, meaning that it can now translocate to the nucleus where
it serves as a key transcription factor (Pathway 1).
Similar to what happens with Pathway 1, LPS-stimulated macro-
phages trigger the activation of TRAM which is known to recruit TRIF to
endosomally associated TLR4 and to activate both NF-κB (relatively late,
in comparison to the MyD88-dependent pathway; Pathway 2a) and
IRF-3 (Pathway 2b). Proteins that are ubiquitinated at K48 as expected,
are substrates and generally become targets for degradation by the
proteasome (red barrels) [19–26]. The MAPK pathway (Pathway 3) is
induced through activation of both MyD88/Mal and TRIF/TRAM path-
ways. A20 deubiquitinates K63-ubiquitinated proteins, whenever its
ubiquitinated substrates are present. Another bacterial agent, CpG
DNA, activates cells via MyD88 only (without the requirement for
TIRAP [Mal]), whereas poly I:C activates cells via the TRIF/TRAMpathway
exclusively.
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proteasome substrates [3], a relatively large number of TLR signaling
and regulatory proteins have been established to be ubiquitinated
and degraded by the proteasome. The UP-pathway that functions to
regulate TLR4 signaling is known to consist of E1, E2, and E3 ligases
(e.g., TRAF6) that covalently ubiquitinate proteins. However, the actual
ubiquitination process is relatively complex; attachment of ubiquitin to
proteins via lysine at the 63rd position of ubiquitin (K63 ubiquitination)
results in the formation of molecular scaffolds that facilitate signaling
events. In contrast, ubiquitination at the K48 position (via lysine at
position 48 of ubiquitin) selectively targets proteins for degradation
by the proteasome [19,20]. LPS signaling through TLR4 promotes
ubiquitination of signaling proteins with both K48- and/or K63-linked
ubiquitin chains leading to selective signaling and/or degradation
events of targeted proteins. The proteasome degrades K48-linked
proteins, while the deubiquitinating enzyme DUB, A20, removes K63-
ubiquitin chains from themolecular scaffolds. These proteins are subse-
quently K48-ubiquitinated, and thereby targeted for proteasome
degradation.
In the following subsections we will summarize our ﬁndings that
center on mechanisms by which the UP pathway might serve as a
potential therapeutic target for the treatment of septic shock and
other inﬂammatory disorders. This information discussed below has
already provided new insights into possibilities for improved under-
standing of regulation of inﬂammatory mediators in general, as well
as development of therapeutic interventions for treatment of other
inﬂammation-related diseases [2,6].
3. The pivotal role of proteasome proteases in modulating
LPS-induced signal transduction and cytokine induction
After initially demonstrating that LPS physically binds to speciﬁc
proteasome subunits, we undertook a series of studies to assess the
potential physiological relevance of these interactions [2]. To this
end, we ﬁrst carried out studies to determine the extent to which LPS
would modulate the proteasome's proteolytic activity. We showed
that, when LPS was added to partially puriﬁed proteasomes in vitro, it
activated the chymotrypsin-like activity of both rabbit muscle and
macrophage proteasomes [2,3]. Given this observation we next under-
took studies to determine the extent towhichwell-deﬁned proteasome
inhibitors might have the capacity to block LPS-induced inﬂammatory
response in macrophages. To address this question, we pretreated
the macrophage-like murine RAW 264.7 cell line in vitro, with the
well-characterized proteasome inhibitor, lactacystin (low dose 5 μM,
that primarily affects the CT-like activity), and observed a dose-
dependent inhibition of LPS-induced cytokine secretion [2,3]. We also
found that the level of expression of many LPS-inducible genes was
markedly inhibited by pretreatment of primary mouse macrophages
with lactacystin, as assessed by real-time RT-PCR. Importantly, expres-
sion of TNF-α gene was a notable exception to this ﬁnding; lactacystin
was not particularly effective at inhibiting its expression following LPS
stimulation of mouse macrophages. Thus, the effects of lactacystin ap-
pear to be at least partially selective within the TLR4 signaling pathway.
Wehave also demonstrated for theﬁrst time, the important role of the
proteasome in regulating the phosphorylation of mitogen activated pro-
tein kinases (MAPKs), since there are three speciﬁc MAPKs, (ERK-1, 2,
JNK-1, 2 and p38 MAPK) that are activated in LPS-stimulated macro-
phages. The addition of lactacystin to macrophages had no detectable ef-
fect on the phosphorylation of ERK-1, 2, however, when macrophages
were pretreated with lactacystin and then treated with LPS, the
levels of this phosphorylation event were greatly reduced. In con-
trast, lactacystin pretreatment alone and lactacystin pretreatment
followed by LPS stimulation resulted in increased levels of phosphor-
ylation of JNK and p38 kinases, thus supporting the concept that the
proteasome differentially regulates the phosphorylation of the three
macrophage associated MAPKs [2]. Although, lactacystin was foundto be effective in inhibiting LPS-induced phosphorylation of ERK 1,
2, it failed to detectably inhibit IRAK-1 associated kinase activity
[2]. Collectively, these results also provide additional support for
the concept that the proteasome is intimately involved in the activa-
tion of many LPS-inducible genes, and that these effects may well be
mediated through the activation of certain upstream IRAKs, MAPKs
and transcription factors.
3.1. Affymetrix gene-chip array analyses of macrophages treated with
LPS and/or proteasome inhibitors and Ingenuity Pathway analysis
We next addressed questions regarding the underlying mechanisms
and consequences of lactacystin treatedmacrophages in terms of the po-
tential to be stimulated by LPS. Pathway analysis using gene-chip array
data revealed that addition of lactacystin to macrophages in culture
markedly affects key inﬂammatory signaling pathways induced by LPS.
Using Affymetrix microarray analysis, we conﬁrmed and extended our
original ﬁndings with lactacystin (in whichwe analyzed a relatively lim-
ited panel of LPS-inducible genes by RT-PCR and Southern blot analysis);
most LPS-induced early genes in murine macrophages were found to be
highly sensitive to inhibition by lactacystin [2,3].We tested lactacystin at
a concentration of 5 μM for the microarray studies because it resulted in
no detectable cellular toxicity over the 5 h experimental time, as
assessed by the MTT (3-(4,5)-dimethylthiozol-2,5-diphenyltetrazolium
bromide) assay. Interestingly, however, and as pointed out earlier at
this concentration, the chymotryptic activity of the proteasomewaspref-
erentially inhibited.
In these studies, we pretreated, in vitro-cultured LPS-responsive
C3HeB/FeJ primary peritoneal macrophages (1×106) without or
with lactacystin for 1 h, followed by stimulation with medium only
or with LPS (10 ng/ml) for 4 h. This experimental protocol, therefore,
allowed us to evaluate the effects of treating macrophages with LPS
alone, lactacystin pretreatment alone, and LPS plus lactacystin pre-
treatment, with untreated macrophages as controls. RNA extraction
and its conversion to cDNA were carried out as described in the
Affymetrix expression analysis technical manual. Our major ﬁndings
from this series of experiments can be summarized as follows:
1. Of 120 geneswhose level of expressionwas upregulated in C3HeB/FeJ
peritonealmacrophages following treatmentwith LPS alone (normal-
ization ratio of 5.0–404), levels of expression of 102 of these genes
were signiﬁcantly reduced by pre-treatment of macrophages with
lactacystin (5 μM). The remaining LPS-induced genes were not
signiﬁcantly suppressed by lactacystin treatment, in part, because
lactacystin alone compensatorily upregulated their expression.
When this unanticipated effect of lactacystin was taken into ac-
count, the results of analysis provided evidence that ~90% of the
LPS-inducible genes could be characterized as being lactacystin-
sensitive.
2. Genes in 14 distinct, well-deﬁned signaling pathways were found to
be affected by LPS, and levels of expression of most of these genes
were inhibited by lactacystin pretreatment. The antigen presentation
pathway (12 genes,MHC classes I and II), NF-κB pathway (42 genes),
death receptor signaling (23 genes), IL-6 signaling (32 genes), IFN-γ
signaling (8 genes), and p38 signaling pathway (23 genes) were
among the key signaling pathways induced in macrophages in re-
sponse to LPS that were inhibited by lactacystin [3].
3. As expected, LPS-induced upregulation of expression of a large
number of key pro-inﬂammatory genes, e.g., IL-1β, IL-1α, IL-6,
TNF-α, IL-12, iNOS, VCAM1, ICAM1, prostaglandin-endoperoxide
synthase 2, endothelin 1, STAT5A, complement component 3, MAIL,
TRAF1, cyclin D2, IL-23α, MAFF, CXCL9, Adrenomedullin, Adenosine
A2a receptor and BCL3was>80% inhibitedwhenmacrophageswere
pretreated with lactacystin [3]. One critical observation, which was
somewhat unexpected was that 5 μM lactacystin blocked LPS-
induced TNF-α gene expression by only 24%, yet this same
Table 1
The Ki values for (50%) inhibition of CT-like (LMP7), T-like (LMP10) and PA (LMP2)
activities of different natural and synthetic proteasome inhibitors. These compounds
are most useful for blocking the proteasome's protease activities that are underlined.
The three protease sites are in close proximity, therefore proteasome inhibitors tend
to affect other sites simultaneously. The advantage of using natural inhibitors over
synthetic inhibitors is that these are non toxic and no cell death was observed at the
concentrations using the MTT assay [6,7].






Lactacystin RAW 264.7 0.6 20 >20
NC-005 RAW 264.7 0.1 3 >20
NC-001 RAW 264.7 ≫20 ≫20 5.0
Resveratrol RAW 264.7 4.0 9.0 b2.7
Quercetin RAW 264.7 25 15 50
Resveratrol THP-1 b2.7 10 10
Quercetin THP-1 20 20 15.8
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IL-6, and IL-12 mRNA expression by >90%. This observation
supported the notion that TNF-α is a cytokine which is induced
by a pathway that may well be different than that required for
IL-1 β, IL-6, and IL-12 and thus dependent upon the protease
site(s) of the proteasome.
Taken collectively, the results of these DNAmicroarray analyses pro-
vided us with novel information that suggested that approximately 90%
of LPS-induced genes (with a normalization ratio of ≥5.0) in macro-
phages are lactacystin-sensitive (i.e. they are dependent upon proteo-
lytic activity of the proteasome). Further, our successful completion of
these studies provided strong evidence that the combined use of the
gene-chip array, coupled with Ingenuity Pathways analysis, can serve
as an informative approach for both conﬁrming the participation of
the proteasome in known signaling pathways, and for identifying addi-
tional novel pathways that are either positively or negatively affected
by lactacystin and, potentially, other novel proteasome inhibitors.
3.2. Lactacystin suppresses peptidoglycan- and CpG DNA-induced
inﬂammatory gene expression and also dysregulates phosphorylation of
MAPK in macrophages
Our studies, summarized above, demonstrated that lactacystin pre-
treatment of macrophages results in the inhibition of most LPS-induced
cytokines, as well as the phosphorylation of MAPK, and that LPS induced
upregulation of TNF-α is relatively resistant to suppression by lactacystin
pretreatment [2]. It is well established that other microbial stimuli, such
as peptidoglycan and bacterial unmethylated CpG DNA, can also trigger
TLR-dependent stimulation of proinﬂammatory cytokine production by
macrophages that may also contribute to the development of systemic
inﬂammation and shock. Therefore, we hypothesized that lactacystin
pretreatment of macrophages would also result in inhibition of pro-
inﬂammatory gene-expression induced by these agonists as well. We
tested this hypothesis by examining the effect of lactacystin in CpG
DNA- and peptidoglycan-induced signaling pathways in RAW 264.7
macrophages. Lactacystin pretreatment once again inhibited, in a
dose-dependent manner, both CpG DNA- and peptidoglycan-induced
expression of TNF-α, IL-1β, and iNOS genes without detectable alter-
ations in β-actin expression or any detectable manifestation of cellular
cytotoxicity [4]. In addition, lactacystin pretreatment also inhibited
both CpG DNA- and peptidoglycan-induced phosphorylation of ERKs.
Collectively, these data strongly support the conclusion that the
proteasome also plays an important role in regulating not only TLR4-
dependent signaling, but also TLR9 (CpG DNA) and TLR2 (peptidogly-
can)-induced signal transduction in macrophages [4,5]. Of importance,
although we have noted that lactacystin pretreatment at low doses
was not a particularly potent inhibitor of LPS-induced TNF-α gene ex-
pression in macrophages, it nevertheless still serves as a potent inhibi-
tor of TNF-α gene expression when CpG DNA was used to stimulate
RAW 264.7 cells in primary mouse macrophages. This observation im-
plies that activation of different TLRs leading to TNF-α gene expression
may involve signaling pathways that show different levels of sensitivity
to proteasome inhibition [4,5].
3.3. The proteasome protease subunits function to regulate LPS-induced
MyD88/TIRAP and TRIF/TRAM signaling pathways
Again, using lactacystin as a relatively selective proteasome inhibitor,
we undertook a series of studies designed speciﬁcally to identify sites in
LPS-induced signaling pathways that are directly, or indirectly, regulat-
ed by the proteasome [1–10]. For these studies, RAW264.7murinemac-
rophages were pretreatedwith either vehicle or lactacystin, followed by
stimulation with LPS (TLR4; MyD88/TIRAP and TRIF/TRAM pathways),
CpG-DNA (TLR9; MyD88 pathway only), poly I:C (TLR3; TRIF pathway
only), or peptidoglycan (TLR2; MyD88/TIRAP pathway). Macrophageactivation by these varied TLR agonists induces gene expression of
iNOS as well as a wide variety of inﬂammatory cytokines, activation of
MAP kinases and several signaling pathways and, in most cases, as
expected lactacystin treatment had a signiﬁcant impact on all of these
TLR agonist induced activities.
More recently, we have explored the relationship between
proteasomal activity and macrophage activation. Our results provided
strong evidence to support the conclusion that the differential prop-
erties of distinct proteolytic subunits of the proteasome play a critical
role in dictating the characteristics of the LPS-induced responses in
mouse macrophages [3,7,8]. To determine the relative contribution
of each individual proteasomal protease in regulating LPS-induced
cytokine production, we used selective inhibitors of the individual
LMP subunits, and in addition performed experiments using macro-
phages obtained from LMP-null mice, the results of which will be sum-
marized below.
3.4. Use of selective proteasome inhibitors to determine function of
proteasomal subunits
Although textbooks of cell biology generally characterize proteasomes
as rather indiscriminate proteolytic complexes (i.e., any ubiquitinated
protein will be indiscriminately degraded by the proteasome), the situa-
tion is now recognized to be signiﬁcantly more complex. We recently
demonstrated, for example, that pretreatment of macrophages with se-
lective proteasome inhibitors (NC-005, NC-001, and lactacystin) to selec-
tively target various protease sites of the proteasome, that murine
constitutive proteasomes (containing X, Y, and Z protease subunits)
and immunoproteasomes (in which LMP subunits have partially rep-
laced X, Y, and Z protease subunits) results in modiﬁcation of several
LPS-induced cellular functions, based on their individual protease activ-
ities [7,8].
In this respect, evidence documenting the differential capacity of
NC-005, NC-001, and lactacystin to inhibit distinct protease activities
of the proteasome is summarized in Table 1. It should be noted that
NC-001 is a comparatively potent inhibitor of PA activity, but is relative-
ly ineffective at inhibiting CT and T enzymatic activities. In contrast,
lactacystin is considerably more effective at inhibiting CT than either T
or PA activity. NC-005 is not a particularly potent inhibitor of PA activity,
but does inhibit both CT and T, though it is considerably more active
against CT than against T. We have also been able to demonstrate that
inhibition of PA activity alone with NC-001 is insufﬁcient to suppress
TNF-α gene expression in LPS-stimulated RAW 264.7 macrophages.
Similarly, concentrations of lactacystin or NC-005 that are sufﬁciently
low enough to inhibit only CT activity, failed to suppress TNF-α gene
expression and TNF-α production, but do suppress iNOS gene expres-
sion and NO production in LPS-stimulated RAW 264.7 macrophages
2091N. Qureshi et al. / Biochimica et Biophysica Acta 1823 (2012) 2087–2093[7]. In contrast, inhibition of both CT- and T-like protease activities,
achieved with higher concentrations of NC-005, markedly reduces
LPS-induced TNF-α production in the absence of measurable effects
on cell viability (90–100%) as assessed by the MTT assay [7]. These
results suggest that CT-like (subunits X, LMP7) and T-like (subunits Z,
LMP10) proteolytic activities must be simultaneously suppressed in
order to inhibit LPS-induced TNF-α production through the proteasome
[7]. As a reminder, we discussed earlier the fact that inhibition of CT-like
activity alone with low concentrations of lactacystin is sufﬁcient to
inhibit NO production by LPS stimulated murine macrophages [7].
3.5. Use of macrophages and splenocytes from LMP knockout mice to
determine function of proteasomal subunits
To begin to dissect where in the signaling pathway that the effects
of lactacystin pretreatment manifest, we capitalized upon the fact
that IFNs are known to have the capacity to amplify the macrophages'
response to TLR agonists. For example, the TRIF/TRAM pathway is
recognized to be responsible for the transcription of IFN-β, protein
after translation then binds to receptors on cells and activates via
autocrine, paracrine mechanisms and Janus kinases (JAK) which
lead to phosphorylation of STAT1 and STAT2. P-STAT1 is known to
be required for the induction of iNOS. Thus IFNs induced via the
TRIF/TRAM (ampliﬁcation) pathway play an amplifying role in the
induction of certain cytokines and NO induction in agonist-treated
cells. Thus IFNs are induced by the TRIF/TRAM pathway and also medi-
ate their effects via the JAK/STAT pathway. We hypothesized that these
agonist-induced pathways are dependent on the proteasome proteases.
One of our major objectives has been to determine the contribution
of selective LMP proteasome protease subunits to TLR-agonist-
induced production of cytokines, activation of signaling mediators, or
to nitric oxide (NO) production in primary murine macrophages and
splenocytes. Our ﬁndings with LMP knockout mice summarized below
have provided novel insights into the pathways of regulation of inﬂam-
matory responses by the macrophage proteasome. As reported above,
LPS induced TNF-α production was essentially normal in peritoneal
macrophages derived from LMP2, LMP7, LMP10 and LMP7/LMP10
double knockout mice [8] allowing the conclusion that these subunits
are not responsible for induction of this cytokine. Therefore, CT-like
and T-like proteasome activities in macrophages of knockout mice
lacking both LMP7 and LMP10 must be attributable solely to subunits
X and Z. Consequently, the capacity of LMP7/LMP10 double knockout
mice to still generate normal levels of production of TNF-α in response
to LPS stimulation suggests that constitutive proteasomes (i.e. lacking
LMP7 and LMP10, but containingX and Z) are fully capable of regulating
signaling mechanisms responsible for TNF-α. LPS induced macrophage
production of NO, iNOS, IRF3, IFN-γ, IL-1β, IL-6, P-STAT1,3; in contrast,
is markedly reduced in LMP7/LMP10 double knockout mice [8], as
shown in Table 2, allowing the conclusion that LMP subunits are essen-
tial for their production while, X, Y, and Z subunits are responsible for
induction of TNF-α in LPS stimulated murine macrophages. Treating
these macrophages with interferons and LPS, however, reverses this
defect, leading to robust NO induction [8]. Collectively, theseTable 2
Levels of gene expression and protein expression of cytokines and signaling mediators
with LPS as the agonist in thioglycollate-elicited macrophages and PMA/ionomycin as
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IL-2Rβ, GATA-3, t-betexperiments clearly demonstrate that NO production is highly depen-
dent on LMP containing immunoproteasomes, while this is not the
case for LPS-induced TNF-α responses. Importantly, TNF-α responses
occur relatively rapidly after LPS exposure (regulated byX, Y, and Z con-
taining constitutive proteasomes within 4 h of stimulation), whereas
NO production occurs much later (within 24 h after stimulation, all-
owing sufﬁcient time for LMP containing immunoproteasomes to be as-
sembled) in normal macrophages.
Next we also wanted to investigate if the proteasome proteases in
splenocytes in the wild type and double knockout mice (C57BL/6) are
also responsible for the agonist-induced cytokines, their receptors and
transcription factors. Since LPS does not directly activate CD4+ T cells,
we used phorbol-12-myristate-13-acetate (PMA)/ionomycin as an ago-
nist, thus bypassing the receptor. LMP7/LMP10-null splenocytes
exhibited reduced levels of gene expression of IL-10, IL-4, IFN-γ,
IL-2Rβ, t-bet and GATA-3 (transcription factors) in response to
agonists, whereas, induction of IL-13, IL-2, TNF-α and IL-2Rα was es-
sentially normal in these knockout mice as compared to wild-type
mice, and was found to be LMP-independent [27] and may therefore
be X, Y, Z-dependent. Lactacystin (which predominantly inhibits
the chymotrypsin-like activity of the proteasome) pretreatment of
LMP7/LMP10-null splenocytes, followed by PMA/ionomycin, re-
duces gene expression of IL-2, IFN-γ, IL-4, IL-13, TNF-α (cytokines),
IL-2Rα and IL-2Rβ (receptors), t-bet and GATA-3 (transcription fac-
tors). In contrast, levels of expression of IL-10 (anti-inﬂammatory
cytokine) were increased upon pretreatment of cells with lactacystin
in splenocytes from null as compared to controls [27]. Thus, as with
macrophages, production of subsets of inﬂammatory cytokines by
stimulated T cells, is inﬂuenced by proteasome subunit composition,
or differential protease activities of cellular proteasomes.
Collectively, these results underscore the importance of LMP sub-
units in the proteasome of macrophages and splenocytes [27]. We
have established that different proteasome proteases regulate levels
of cytokine gene expression and protein expression differentially.
4. Signaling proteins accumulate in macrophages upon treatment
with LPS and lactacystin that are normally degraded by
the proteasome
Lactacystin, (low levels, 2.5 μM) binds to chymotrypsin-like binding
sites in the proteasome and it blocks the degradation of ubiquitinated
proteins [7]. We have identiﬁed several signaling proteins such as
IRAK-1, TRAF6, IRF3, P-STAT1 and P-IκB-α that accumulate in RAW
264.7 cells after they have been pretreated with low dose lactacystin,
followed by stimulation with LPS, suggesting that these signaling pro-
teins are degraded via the CT-like activity of the proteasome.
5. Proposed model for the role of proteasomes in signaling
Interactions between LPS and the TLR4/MD2 complex are known
to lead to the recruitment of two pairs of adapter molecules to
TLR4, speciﬁcally TIRAP (Mal)/MyD88 and TRAM/TRIF [18–22]. TLR4
becomes ubiquitinated by a series of enzymes, E1, E2, and E3 ligases,
and is degraded rapidly within 10–30 min, (our unpublished data) by
proteasomes that contain predominantly the constitutively expressed
X, Y, and Z subunits. These proteasomes have CT/PA ratios of ~1.0 in
RAW 264.7 cells. LPS stimulation leads to a cascade of events that
phosphorylate IκB, which then becomes ubiquitinated with the K48-
linked ubiquitin, and thereby targets IκB for proteasome degradation.
This allows the activation of NF-κB, which translocates to the nucleus
and induces gene expression of TNF-α and other proinﬂammatory
cytokines. Both CT-like and T-like activities associated with subunits
X and Z, are responsible for LPS-induced TNF-α, while the CT-like
activity appears to be required for LPS-induced gene expression of
other proinﬂammatory cytokines [7,8]. Through this pathway, LPS
stimulates the synthesis and secretion of TNF-α and induces new
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ized predominantly by the presence of LMP7, LMP2, and LMP10
proteolytic subunits (CT/PA ratio ~4.5, RAW 264.7 cells), that are ac-
cordingly, characterized by increased CT-like and T-like activities,
with correspondingly decreased PA activity (relative to X, Y, and Z
subunits) [7]. Differences in the relative speciﬁcity of these new pro-
tease activities lead to differential cleavage of the already generated
signaling proteins. The TRIF/TRAM pathway is activated upon endocy-
tosis of LPS [28,29], and this latter event ultimately leads to genera-
tion of NO, and other mediators whose production is dependent on
the TRIF/TRAM pathway and through production of IFN-β. RAW
264.7 cells can also be induced to produce NO by LPS and IFN-γ,
thus bypassing the TRIF/TRAM pathway, although these cells remain
potent inducers of TNF-α in response to LPS. In conclusion; activation
and regulation of both LPS-induced pathways are critically dependent
on the presence of speciﬁc proteasome proteases in RAW 264.7 cells
[7]. After use, the proteasome subunits are ubiquitinated at speciﬁc
lysines and degraded by the proteasome itself (Fenselau and Qureshi,
unpublished data).
The signaling pathways in C57BL/6mousemacrophages in response
to LPS are somewhat more complex. In contrast to RAW 264.7 cells,
both resident and thioglycollate-elicited macrophages from C57BL/6
mice contain “mixed proteasomes” containing both X, Y, Z, and LMP7,
LMP2, and LMP10 proteasome protease subunits. The macrophages
obtained via the peritoneal lavage from the C57BL/6mouse can be read-
ily induced to generate cytokines, such as TNF-α; and alsoNO efﬁciently
in response to LPS. LPS-induced TNF-α by these cells is dependent on X,
Y and Z subunits, while IL-1β, IL-6, IFN-β and IL-12 are dependent on
the presence of LMP subunits of the proteasome [8]. We have shown
that levels of signaling proteins and enzymes, such as P-IRF3, iNOS,
IFN-β, IFN-γ, P-STAT1, and P-STAT3 (S727); and levels of gene expres-
sion of cytokines, such as IL-1β, IL-6, IL-12; and NO production are
reduced in LPS-stimulated macrophages from LMP7/LMP10 double
knockout mice, thus underscoring the importance of LMP subunits to
production of these effector molecules. The TRIF/TRAM pathway also
functions to activate NF-κB [8] (Pathway 2a). Macrophages from LMP
knockout mice show intrinsic defects in the TRIF/TRAM pathway [8],
which can be overridden by the addition of IFN-γ. Thus, the availability
of mixed proteasomes appears to be important for LPS-induced synthe-
sis of NO in macrophages. In contrast, LPS-induced TNF-α, and the
MyD88 pathway are still able to function normally in macrophages
from LMP knockout mice, albeit at a lower level [8]. Once again, we
would conclude that the type of proteasome proteolytic subunits
dictates the speciﬁc cellular response to LPS and associated signaling
events.
6. Screening of small molecules for use as potential proteasome
inhibitors. Several natural compounds and licensed drugs act at
the proteasome level
In preliminary experiments, we have found that pretreatment of
mice with lactacystin [2] and pretreatment of mice with mevinolin
(structurally related to lactacystin) are both effective in protecting
galactosamine-sensitized mice and cecal-ligation and puncture mice
from LPS-induced mortality, and both are known to function as inhibi-
tors of proteasome activities [6]. Mevinolin (closed ring form of lova-
statin, normally lovastatin is 80% open ring and 20% closed ring form)
is well-established as a cholesterol-lowering compound, and has been
shown to function as a competitive inhibitor for the β-hydroxy-β-
methylglutaryl coenzyme A reductase, the rate-limiting enzyme in the
biosynthesis of cholesterol. Results of recent investigations by others
have shown that mevinolin can act as a proteasome inhibitor [30] in
MDA-MB-157 tumor cells, and serve to either increase or decrease in-
ﬂammation, depending on relative dose. Both lactacystin andmevinolin
are β-lactones. Therefore, we queried the extent to which other FDA-
approved drugs or natural compounds with complex lactone structuresmight alsomanifest inhibitory activity at the proteasome level.We have
now screened several known drugs and natural compounds that would
be predicted to function as anti-inﬂammatory compounds in vitro [31–
33]. We have evaluated their relative effect on the three protease activ-
ities (CT, T and PA) of the puriﬁed 20S proteasome of rabbit muscle and
also by using the Pro-Glo proteasome protease enzymatic assays in
macrophages [31–33]. We also tested the inhibition of expression of
LPS-induced cytokines of several drugs in several experimental models
[31–34] and degradation of P-IκB to determine the extent to which
these compounds may function at the level of the proteasome when
added before and after LPS treatment of primary cultured mouse
macrophages in vitro and in vivo [31–33]. We identiﬁed mevinolin,
quercetin (present in berries and other natural fruits and vegetables),
resveratrol (compound found in red wine) and as the positive control,
lactacystin, as compounds that function as potent anti-inﬂammatory
agents and cause inhibition of LPS-induced gene expression levels of
iNOS and TNF-α, IL-6, IL-1β; activation of NF-κB, and NO in macro-
phages. Importantly, using this approach, we identiﬁed quercetin and
resveratrol for the ﬁrst time, as potent proteasome inhibitors, by the
data summarized in Table 1. The advantage of using natural inhibitors
over synthetic inhibitors is that these have already been established to
be non-toxic and no detectable cell death has been observed at any
concentration tested using the MTT assay.
7. Quercetin's and resveratrol's (proteasome inhibitors) activities
are similar to that of lactacystin, but these agents are considerably
less toxic
Lactacystin has been extensively employed as an effective anti-
inﬂammatory compound, but it is relatively toxic to cells primarily
because it functions as an irreversible proteasome inhibitor. To assess
the differential effects of lactacystin, quercetin and resveratrol on cellu-
lar toxicity, we treated RAW 264.7 cells with each of these agents at a
variety of concentrations and monitored cell-death at different time
points using the MTT assay as described previously [7, unpublished].
We found that, for up to 8 h, none of the compounds induced signiﬁcant
cell death. However, after 24 h, lactacystin, even at doses as low as
6.5 μM, was toxic to those cells, whereas quercetin and resveratrol did
not detectably kill the cells even at 100 μM. The results from these
experiments provided a strong rationale for our studies to identify
novel compounds that have anti-inﬂammatory effects similar to
lactacystin, but are relatively non-toxic. The data on Ki values shown
in Table 1 have been obtained in RAW264.7 and THP-1 (humanmono-
cytes) cells. There are differences in the Ki values of inhibitors with
RAW 264.7 and THP-1 cells, because these cells contain different
proteasome subunits. Our experiments clearly suggested that quercetin
and resveratrol both function as potent proteasome inhibitors and can
be used to inhibit inﬂammation, without the deleterious effects.
8. Proteasome inhibitors, in combination with antibiotics, provide
protection in a CLP model of polymicrobial septic shock
Since septic shock occurs primarily due to production of excessive
levels of inﬂammation, we sought to assess the potential clinical sig-
niﬁcance of these proteasome inhibitors in vivo in a cecal ligation and
puncture (CLP) model of polymicrobial sepsis. Co-administration of
either mevinolin or quercetin with standard antibiotic therapy
(Primaxin) afforded signiﬁcantly greater protection against septic
shock in a mouse CLP model than either treatment alone. In untreated
mice, model resulted in 95% 3-day mortality, and this was reduced to
70% with mevinolin alone, 58% with Primaxin alone, but was reduced
drastically to 35% using a combination of mevinolin and Primaxin.
The combination of quercetin and Primaxin showed similar results.
These studies strongly support the conclusion that therapeutic
targeting of cellular proteasomes to dampen mediator production
[31], in conjunction with standard antimicrobial therapy, may be of
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ing the cytokine storm normally elicited in sepsis [6].
9. Summary of ﬁndings
In this review, we have summarized our recent ﬁndings that center
on themechanisms involving the proteasome as a potential therapeutic
target in the treatment of inﬂammation. LPS treated RAWmacrophages
manifest altered relative levels of XYZ/LMP protease subunits and asso-
ciated proteolytic activities of the cellular proteasome. Our collective
evidence would strongly support the conclusion that the proteasome
proteases serve as pivotal regulators of LPS-induced inﬂammation in
macrophages. These functions include modulation of: levels of gene
expression, generation of speciﬁc transcription factors, degradation of
proteins involved in cell metabolism, relative rates of degradation of
proteins involved in multiple signaling pathways, relative levels of
cytokines secreted, NO production, and cell death/growth. Therapeutic
targeting of cellular proteasomes, in conjunction with standard antimi-
crobial therapy, may be of considerable survival beneﬁt in treatment of
septic shock by mitigating the ‘cytokine storm’ normally observed in
sepsis. Defects in structure/function of proteasome subunits caused by
genetic disorders (such as shown in knockout mice) [8], aging [31],
diet (quercetin, resveratrol) [31–34, Qureshi, unpublished data], or
drugs [lovastatin] [6] contribute to changes in proteasome's protease
activity. Natural proteasome inhibitors/activators can potentially be
used as therapeutic response modiﬁers to prevent/treat diseases
based on inﬂammation.
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